Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 34.17m |
Free float | 32.87m |
P/E (TTM) | -- |
Market cap | 683.34m USD |
EPS (TTM) | -1.82 USD |
--
More ▼
Press releases
- Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
- BrainTransporter™ dramatically improves antibody delivery to the brain
- Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
- Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
- Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
- Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
- Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
- Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
- Eisai will request reconsideration of initial decision for lecanemab in Australia
More ▼